To date there is limited data on the immune profile and outcomes of solid organ transplant recipients who encounter COVID-19 infection early post-transplant. Here we present a unique case where the kidney recipient’s transplant surgery coincided with a positive SARS-CoV-2 test and the patient subsequently developed symptomatic COVID-19 perioperatively. We performed comprehensive immunological monitoring of cellular, proteomic, and serological changes during the first 4 critical months post-infection. We showed that continuation of basiliximab induction and maintenance of triple immunosuppression did not significantly impair the host’s ability to mount a robust immune response against symptomatic COVID-19 infection diagnosed within the first week post-transplant.

迄今为止，关于在移植后早期遇到 COVID-19 感染的实体器官移植受者的免疫特征和结果的数据有限。在这里，我们介绍了一个独特的案例，肾脏受者的移植手术与 SARS-CoV-2 检测呈阳性同时发生，患者随后在围手术期出现了有症状的 COVID-19。我们在感染后的前 4 个关键月份对细胞、蛋白质组学和血清学变化进行了全面的免疫学监测。我们表明，继续巴利昔单抗诱导和维持三重免疫抑制并未显着损害宿主针对移植后第一周内诊断出的有症状的 COVID-19 感染产生强大免疫反应的能力。